Journal of Pharmacology and Experimental Therapeutics

Journal of Pharmacology and Experimental Therapeutics
Title	Journal of Pharmacology and Experimental Therapeutics
Editor	John A. Hey (Editor-in-Chief)
Discipline	Pharmacology, Toxicology
Publisher	American Society for Pharmacology and Experimental Therapeutics
Country	United States
History	1909–present
Frequency	Monthly
Openaccess	Hybrid
Impact	4.4
Impact-year	2022
ISSN	0022-3565
EISSN	1521-0103
OCLC	01798757
Website	https://jpet.aspetjournals.org/
Former names	*Journal of Pharmacology and Experimental Therapeutics*

Journal of Pharmacology and Experimental Therapeutics. It is a premier peer-reviewed monthly scientific journal publishing original research on the interactions of chemicals with biological systems. Established in 1909, it is the official publication of the American Society for Pharmacology and Experimental Therapeutics and covers a broad spectrum including molecular, cellular, and in vivo pharmacology, as well as toxicology and translational medicine. The journal is renowned for its rigorous standards and has been a foundational platform for seminal discoveries in drug action, receptor biology, and metabolic pathways.

History and scope

The journal was founded in 1909 by the American Society for Pharmacology and Experimental Therapeutics, an organization itself established with support from the Carnegie Institution for Science. Its early volumes documented foundational work in an era defined by discoveries like the mechanism of action of acetylcholine and the characterization of adrenergic receptors. Historically, editors-in-chief have included prominent figures like K. K. Chen and Julius Axelrod, a Nobel Prize in Physiology or Medicine laureate. The scope encompasses all aspects of pharmacodynamics and pharmacokinetics, from studies on G protein-coupled receptors and ion channels to investigations of drug metabolism by enzymes like the cytochrome P450 system and research in neuropharmacology and cardiovascular pharmacology.

Abstracting and indexing

The journal is comprehensively abstracted and indexed in major scientific databases, ensuring global dissemination of its research. It is covered by services including PubMed, MEDLINE, the Science Citation Index Expanded, and Scopus. It is also included in Chemical Abstracts Service and BIOSIS Previews. This indexing in resources like the Web of Science and EMBASE facilitates discovery by researchers at institutions like the National Institutes of Health and Harvard University, making its content central to literature searches in biomedical sciences.

Impact and metrics

According to the Journal Citation Reports, it had an impact factor of 4.4 for the 2022 citation year. While its impact factor has seen historical fluctuations, it maintains a strong reputation for quality in the fields of pharmacology and pharmacy. The journal's CiteScore and SCImago Journal Rank also reflect its standing. A significant portion of its citations come from papers published in other high-profile journals such as Nature, Science, and Proceedings of the National Academy of Sciences of the United States of America, indicating its influence on broad biomedical research.

Editorial board and policies

The editorial board is led by an Editor-in-Chief, currently John A. Hey, and includes senior editors and a large international panel of experts from institutions like the University of California, San Francisco and the Mayo Clinic. The journal employs a rigorous single-anonymized peer review process. It offers a hybrid open access publishing model and adheres to ethical guidelines set by bodies like the International Committee of Medical Journal Editors and the Committee on Publication Ethics. All manuscripts must comply with policies regarding research involving subjects from the World Medical Association.

Notable articles and contributions

The journal has published numerous landmark studies that have shaped modern pharmacology. Seminal work by Julius Axelrod on catecholamine metabolism and neurotransmitter reuptake appeared in its pages. It published early characterizations of opioid receptors by Solomon Snyder and Candace Pert, and foundational studies on benzodiazepine receptors. Other notable contributions include pivotal research on angiotensin-converting enzyme inhibitors, the pharmacokinetics of chemotherapeutic agents, and mechanistic studies of drugs like propranolol and cimetidine that revolutionized clinical practice.

Related publications and society affiliation

As the flagship journal of the American Society for Pharmacology and Experimental Therapeutics, it is part of a family of publications that includes Molecular Pharmacology, Pharmacological Reviews, and Drug Metabolism and Disposition. The society also collaborates on initiatives with the Federation of American Societies for Experimental Biology. The journal's content is often presented at the society's annual meeting, Experimental Biology, and it shares an editorial and publishing platform with other society journals, fostering an integrated knowledge base for the global pharmacology community.

Category:Pharmacology journals Category:Publications established in 1909 Category:Monthly journals Category:American Society for Pharmacology and Experimental Therapeutics